Stay Connected

Myeloma Mentors: Charting New Paths in Relapsed/Refractory Multiple Myeloma Care

Webinar/Online

Thursday, October 23, 2025 at 5:00pm ET - 6:00pm ET
Add this event to your calendar

Info

Topic

Join leading experts and peers to advance care in relapsed/refractory multiple myeloma (RRMM). Stay ahead in the rapidly evolving treatment landscape of relapsed/refractory multiple myeloma (RRMM). With bispecific antibodies (BsAbs) and CAR T-cell therapies transforming care, healthcare professionals face new challenges in sequencing therapies, managing toxicities, and ensuring continuity across academic and community settings. This CME-certified program brings together expert faculty and community clinicians through interactive mentorship sessions featuring case-based discussions. Participants will gain practical, evidence-based insights to strengthen decision-making and enhance patient care.

Credits Offered

This event offers 1.0 contact hour to attendees.
Accreditation Info: ANCC & ACCME.

Additional Information
Advances in bispecific antibodies (BsAbs) and CAR T-cell therapy have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). However, with rapid developments come significant challenges: integrating novel agents into patient-specific care plans, sequencing therapies appropriately, and managing unique toxicities such as cytokine release syndrome (CRS) and ICANS. Variability in protocols and transitions between academic and community oncology settings further contribute to fragmented care.
In partnership with the University of Colorado Hematology Division, this accredited educational initiative brings together leading hematology experts and community clinicians to address these critical gaps. Through interactive mentorship sessions, case-based discussions, and enduring webcasts, participants will gain the tools needed to optimize therapy selection, sequencing, and toxicity management in RRMM. A dedicated provider toolkit and non-certified social media broadcasts will further extend the reach and impact of the program, supporting equitable access to evidence-based care across diverse practice environments.
By fostering collaboration between academic centers and community oncology practices, this program empowers clinicians to improve continuity of care, implement best practices, and ultimately enhance patient outcomes.

Target Audience

This educational program is directed at hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM.

Upon completion of this activity, the participant should be able to:

  • Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.
  • Construct patient-specific treatment sequences incorporating BsAbs into existing treatment plans based on prior treatments, disease characteristics, and comorbidities.
  • Implement evidence-based strategies for mitigating and managing CRS and neurological toxicities associated with BsAbs in both inpatient and outpatient settings, including step-up dosing protocols, specific monitoring parameters, and thresholds for intervention.
  • Formulate a structured communication plan between academic and community practitioners to ensure safe transitions of care for patients receiving BsAbs.

Speakers

Joseph Mikhael
Joseph Mikhael MD, MED, FRCPC, FACP, FASCO

Professor, Translational Genomics Research Institute - City of Hope Cancer Center,
Chief Medical Officer - International Myeloma Foundation

Jorge Monge Urrea
Jorge Monge Urrea MD

Dr. Jorge Monge Urrea is a hematologist in Aurora, Colorado. He received his medical degree from Universidad Anahuac School of Medicine and has been in practice between 11-20 years. Dr. Jorge Monge Urrea has expertise in treating lymphoma, among other conditions - see all areas of expertise

Dan Sherbenou
Dan Sherbenou MD, PHD

Associate Professor, Medicine – Hematology
University of Colorado
Aurora, Colorado

Kaylee Timlin
Kaylee Timlin MSN, BS

Instructor of Medicine, Hematology
University of Colorado
Aurora, Colorado

Interested in attending this event?

Enter your email address below to register for this event.
If you do not have an account, create your account.